Amicus Therapeutics (NASDAQ:FOLD) 2011 Second Half Looks Strong

Amicus Therapeutics (NASDAQ:FOLD) has a number of catalyst in the pipeline in the second half of 2011 that could give a big boost to the share price of the company.

Canaccord says, "FOLD update at JPM: Amigal pivotal data H2/11E, multiple 2011 pipeline catalysts. Positive H2/11 pivotal Fabry Amigal data may be a transformational catalyst. FOLD may also have good Phase 2 proof-of-concept chaperone/enzyme combotherapy data in Fabry and Pompe H2/11E. Our $7 target is based on a pNPV analysis."

Canaccord Genuity maintains a "Buy" rating on Amicus Therapeutics, which closed Wednesday at $4.69, gaining $0.10, or 2.18 percent.